# Shree Ganesh Re (NSE: SGRL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SGRL · Pivot · prices to 22 Oct 2026

Shree Ganesh Re (NSE: SGRL) closed at ₹658.25 on 22 Oct 2026, up 3.32% on the day. With a market capitalisation of ₹845 Cr, it ranks 1546th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 47.7× trailing earnings, against a return on equity of 10.9% in FY26. Its 52-week range is ₹477.05 (17 Aug 2026) to ₹749.85 (23 Sep 2026); the last close is 12.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹33 Cr (+35.9% year on year) and net profit ₹6 Cr (−4.9%), on a consolidated basis. Promoters held 72.84% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹658.25 |
| Market cap | ₹845 Cr |
| P/E (trailing) | 47.7 |
| ROE | 10.9% (FY26) |
| ROCE | 14.8% (FY26) |
| Debt to equity | 0.19 |
| 52-week high | ₹749.85 (23 Sep 2026) |
| 52-week low | ₹477.05 (17 Aug 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹33 Cr | +35.9% | ₹6 Cr | −4.9% | ₹4.88 |
| Q3 FY26 | ₹21 Cr | −22.0% | ₹3 Cr | −43.0% | ₹2.41 |
| Q2 FY26 | ₹30 Cr | −6.2% | ₹5 Cr | −22.6% | ₹3.86 |
| Q1 FY26 | ₹25 Cr | −0.4% | ₹3 Cr | −25.8% | ₹2.68 |
| Q4 FY25 | ₹24 Cr | −34.6% | ₹7 Cr | −47.6% | ₹5.13 |
| Q3 FY25 | ₹27 Cr | — | ₹5 Cr | — | ₹4.22 |
| Q2 FY25 | ₹32 Cr | — | ₹6 Cr | — | ₹4.97 |
| Q1 FY25 | ₹25 Cr | — | ₹5 Cr | — | ₹3.62 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹109 Cr | ₹23 Cr |
| FY24 | ₹126 Cr | ₹28 Cr |
| FY20 | ₹64 Cr | ₹10 Cr |
| FY19 | ₹35 Cr | ₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.84%
- Domestic institutions: 0.52%
- Non-institutions: 26.64%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Themis Medicare](https://app.pivotnow.in/stock/THEMISMED) | ₹98.08 | ₹903 Cr | — | — |
| [Anuh Pharma](https://app.pivotnow.in/stock/ANUHPHR) | ₹80.29 | ₹805 Cr | 19.6 | — |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |
| [Vikram Thermo](https://app.pivotnow.in/stock/VIKRAMTH) | — | ₹728 Cr | — | — |
| [Zim Laboratories](https://app.pivotnow.in/stock/ZIMLAB) | ₹133.50 | ₹715 Cr | 112.2 | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |

## Questions and answers

### What is the share price of Shree Ganesh Re today?

Shree Ganesh Re (NSE: SGRL) last closed at ₹658.25 on 22 Oct 2026. Its 52-week high is ₹749.85 and its 52-week low is ₹477.05.

### What is the market cap of Shree Ganesh Re?

Shree Ganesh Re's market capitalisation is ₹845 Cr (₹845 Cr) at the 22 Oct 2026 close, ranking 1546th among the NSE companies Pivot tracks.

### What is the P/E ratio of Shree Ganesh Re?

Shree Ganesh Re trades at a trailing P/E of 47.7. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 24.2.

### What is the ROE and ROCE of Shree Ganesh Re?

Return on equity was 10.9% in FY26 and return on capital employed was 14.8% in FY26 (consolidated figures).

### Is Shree Ganesh Re a debt-free company?

No. Shree Ganesh Re's debt-to-equity ratio was 0.19 in FY26, with total debt of ₹21 Cr.

### What were Shree Ganesh Re's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Shree Ganesh Re reported revenue of ₹33 Cr, +35.9% year on year, and net profit of ₹6 Cr, −4.9% year on year.

### What is the shareholding pattern of Shree Ganesh Re?

As of 30 Jun 2026: promoters 72.84%, domestic institutions 0.52%, non-institutions 26.64%.

### Who are Shree Ganesh Re's competitors?

The listed Pharma & Healthcare companies closest to Shree Ganesh Re by market cap are Themis Medicare, Anuh Pharma, Kilitch Drugs (India), Vikram Thermo, Zim Laboratories and Valiant Laboratories.

### Is Shree Ganesh Re a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Shree Ganesh Re's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SGRL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.